4-(1H-imidazol-4-yl)butanoic acid | 25651-69-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(1H-imidazol-4-yl)butanoic acid
• 英文别名: 4-(1(3)H-imidazol-4-yl)-butyric acid；4-(1(3)H-Imidazol-4-yl)-buttersaeure；4-(1H-imidazol-5-yl)butanoic acid
• CAS: 25651-69-8
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD08668424
• 分子量: 154.169
• InChiKey: WYMOPTUEZWGCKJ-UHFFFAOYSA-N

物化性质

• 沸点：
  424.2±20.0 °C(Predicted)
• 密度：
  1.269±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1H-imidazol-4-yl)butanoic acid 在 硼烷四氢呋喃络合物 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 {2-[2-(3,5-Dimethyl-phenyl)-1H-indol-3-yl]-ethyl}-[4-(1H-imidazol-4-yl)-butyl]-amine
  参考文献：
  名称：

  Heterocyclic Derivatives of 2-(3,5-Dimethylphenyl)tryptamine as GnRH Receptor Antagonists

  摘要：

  A series of heterocyclic 2-(3,5-dimethylphenyl)tryptamine derivatives was prepared and evaluated on a rat gonadotropin releasing hormone receptor assay. The carbon tether length and heterocyclic ring attached to the amino group of 2-(3,5-dimethylphenyl)tryptamine were varied. Several of these derivatives were potent GnRH antagonists with the most potent compound having an IC50 of 16nM. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00133-0
• 作为产物：
  描述：

  sodium diethylmalonate 、 4-(2-氯乙基)咪唑盐酸盐 在 乙醇 作用下， 生成 4-(1H-imidazol-4-yl)butanoic acid
  参考文献：
  名称：

  Imidazole Catalysis. V. The Intramolecular Participation of the Imidazolyl Group in the Hydrolysis of Some Esters and the Amide of γ-(4-Imidazolyl)-butyric Acid and 4-(2'-Acetoxyethyl)-imidazole²

  摘要：

  DOI：

  10.1021/ja01520a062

文献信息

• Acylated and alkylated histamine derivatives as new histamine H3-receptor antagonists
  作者：H Stark、R Lipp、JM Arrang、M Garbarg、JC Schwartz、W Schunack

  DOI：10.1016/0223-5234(94)90031-0

  日期：1994.1

  New histamine H-3-receptor antagonists were prepared and investigated for their ability to increase synthesis and release of histamine mediated by inhibition of presynaptically located H-3-receptors. Acyl derivatives of histamine methylated at different positions show poor activity at H-3-receptors, whereas N-alpha-alkyl and particularly N-alpha-acyl derivatives of histamine possess moderate to good H-3-receptor antagonist activity. A not-too-bulky and lipophilic residue in an optimal distance of 3-4 methylene groups from the amide function leads to potent and selective H-3-receptor antagonists. N-alpha-Histamine-gamma-phenylbutyramide 11 and N-alpha-histamine-gamma-cyclohexylbutyramide 13 are H-3-receptor antagonists with -log K-i of 7.1 and 7.3, respectively. Structure-activity relationships of different substitution patterns are discussed.
• COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS
  申请人：Uysal Teoman

  公开号：US20090131384A1

  公开（公告）日：2009-05-21

  The invention provides novel compounds, methods for treating or preventing a condition related to ER-stress, e.g. hypercholesterolemia, atherosclerosis and related conditions, and pharmaceutical compositions related thereto.
• LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT
  申请人：Chi Mei Corporation

  公开号：US20170152443A1

  公开（公告）日：2017-06-01

  A liquid crystal alignment agent allowing formation of an LCD element having good reliability and less residual image, a liquid crystal alignment film, and an LCD element having the liquid crystal alignment film are shown. The liquid crystal alignment agent includes a polymer (A), a photosensitive polysiloxane (B), and a solvent (C). The polymer (A) is obtained by reacting a mixture that includes a tetracarboxylic dianhydride component (a-1) and a diamine component (a-2). The photosensitive polysiloxane (B) is obtained by reacting a polysiloxane (b-1) having an epoxy group with a cinnamic acid derivative (b-2) and an aromatic heterocyclic derivative (b-3) containing nitride, oxide or sulfide.
• [EN] COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS<br/>[FR] COMPOSÉS ET MÉTHODES POUR TRAITEMENT DE TROUBLES ASSOCIÉS À UN STRESS DU RÉTICULUM ENDOPLASMIQUE
  申请人：SYNDEXA PHARMACEUTICALS CORP

  公开号：WO2007111994A2

  公开（公告）日：2007-10-04

  [EN] The invention provides novel compounds, methods for treating or preventing a condition related to ER-stress, e.g. hypercholesterolemia, atherosclerosis and related conditions, and pharmaceutical compositions related thereto.
  [FR] L'invention permet d'obtenir de nouveaux composés et des méthodes pour traiter ou prévenir une condition en rapport avec un stress du réticulum endoplasmique, comme par exemple une hypercholestérolémie, une athérosclérose et des conditions apparentées, et des compositions pharmaceutiques en relation avec cela.
• Heterocyclic Derivatives of 2-(3,5-Dimethylphenyl)tryptamine as GnRH Receptor Antagonists
  作者：Peter Lin、Mamta Parikh、Jane-Ling Lo、Yi Tien Yang、Kang Cheng、Roy G Smith、Michael H Fisher、Matthew J Wyvratt、Mark T Goulet

  DOI：10.1016/s0960-894x(01)00133-0

  日期：2001.4

  A series of heterocyclic 2-(3,5-dimethylphenyl)tryptamine derivatives was prepared and evaluated on a rat gonadotropin releasing hormone receptor assay. The carbon tether length and heterocyclic ring attached to the amino group of 2-(3,5-dimethylphenyl)tryptamine were varied. Several of these derivatives were potent GnRH antagonists with the most potent compound having an IC50 of 16nM. (C) 2001 Elsevier Science Ltd. All rights reserved.